Nabilakhyar (Talk | contribs) |
Nabilakhyar (Talk | contribs) |
||
Line 31: | Line 31: | ||
<h1 style="text-align: center;"><strong>Improvement on Downstream Processing</strong></h1> | <h1 style="text-align: center;"><strong>Improvement on Downstream Processing</strong></h1> | ||
<div class="column two_third_size"> | <div class="column two_third_size"> | ||
− | <p style="text-align: justify;">Another constraints that the PHBV production is currently facing which hinder its commercialisation is the inefficient downstream processing which includes PHBV recovery from the microbial cells. This point is supported by our Life Cycle Assessment as well as our discussion with Cambridge Consultant (?). To address this issue, we propose an in-situ secretion system by the E. coli which potentially will be more environmentally friendly and time-efficient.</p> | + | <p style="text-align: justify;">Another constraints that the PHBV production is currently facing which hinder its commercialisation is the inefficient downstream processing which includes PHBV recovery from the microbial cells. This point is supported by our <a href="https://2018.igem.org/Team:Edinburgh_OG/life_cycle_assessment">Life Cycle Assessment as well as our discussion with <a href="https://2018.igem.org/Team:Edinburgh_OG/Human_Practices">Cambridge Consultant (?). To address this issue, we propose an in-situ secretion system by the E. coli which potentially will be more environmentally friendly and time-efficient.</p> |
<h2>The phasin and hemolysin secretion system (hemolysin BD and hemolysin A)</h2> | <h2>The phasin and hemolysin secretion system (hemolysin BD and hemolysin A)</h2> | ||
<h3><strong>Overview</strong></h3> | <h3><strong>Overview</strong></h3> |
Revision as of 11:35, 13 October 2018